In Vitro and In Vivo Imaging of Prostate Cancer Angiogenesis Using Anti-Vascular Endothelial Growth Factor Receptor 2 Antibody-Conjugated Quantum Dot.
- Author:
Haejin KWON
1
;
Jiyeon LEE
;
Rita SONG
;
Sung Il HWANG
;
Junghan LEE
;
Young Hwa KIM
;
Hak Jong LEE
Author Information
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords: Quantum dot; VEGFR2; Angiogenesis; Prostate cancer; Near infrared
- MeSH: Animals; Carbodiimides/pharmacology; Cell Line, Tumor; Disease Models, Animal; Electrophoresis, Agar Gel; Fluorescence; Male; Mice; Mice, Nude; Microscopy, Confocal; Neovascularization, Pathologic/*pathology; Prostatic Neoplasms/*pathology; *Quantum Dots; Succinimides/pharmacology; Transplantation, Heterologous; Vascular Endothelial Growth Factor Receptor-2/*antagonists & inhibitors
- From:Korean Journal of Radiology 2013;14(1):30-37
- CountryRepublic of Korea
- Language:English
- Abstract: OBJECTIVE: Authors aimed to determine the targeting ability of vascular endothelial growth factor receptor 2 (VEGFR2)-conjugated quantum dots (QDs) in vitro, and apply it for a xenograft prostate cancer mouse model. MATERIALS AND METHODS: Conjugation reaction of QDs was performed by using the N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide (EDC) and sulfo-(N-hydroxysulfosuccinimide) (Sulfo-NHS). The human umbilical vein cord endothelial cells (HUVECs) were incubated with QDs, conjugated with antiVGFR2, to see a specific binding in vitro. Fluorescent cell images were taken by a confocal microscope. The human prostate cancer cells (PC3) were injected to five nude mice on hind limbs to make the xenograft tumor model. QD-antiVEGFR2 antibody complex was injected into the tumor model and fluorescence measurements were performed at 1, 4, 9, 12, 15, and 24 hours after the injection. RESULTS: The specific interaction between HUVECs and QD-antiVEGFR2 antibody was clearly shown in vitro. The in vivo fluorescence image disclosed that there was an increased signal of tumor, 12 hours after the injection of QDs. CONCLUSION: By showing endothelial cells binding with QDs-antiVEGFR2 antibodyand an experimental application of the antibody for VEGFR2 imaging in the prostate cancer xenograft mouse model, we suggests that the antibody-conjugated QDs can be a potential imaging tool for angiogenesis of the cancer.
